Drug Shortage Report for TRIESENCE
| Report ID | 140457 |
| Drug Identification Number | 02368676 |
| Brand name | TRIESENCE |
| Common or Proper name | Triesence 1mL Susp |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | TRIAMCINOLONE ACETONIDE |
| Strength(s) | 40MG |
| Dosage form(s) | SUSPENSION |
| Route of administration | INTRAVITREAL INTRAVITREAL |
| Packaging size | 1mL |
| ATC code | S01BA |
| ATC description | ANTIINFLAMMATORY AGENTS |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | 2021-10-11 |
| Actual start date | 2021-10-14 |
| Estimated end date | 2022-01-14 |
| Actual end date | 2021-12-22 |
| Shortage status | Resolved |
| Updated date | 2022-01-04 |
| Company comments | Production constraints limit product availability. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2021-07-13 | English | Compare |
| v2 | 2021-06-04 | French | Compare |
| v1 | 2021-06-04 | English | Compare |